XML 100 R94.htm IDEA: XBRL DOCUMENT v3.25.1
Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Sep. 30, 2024
Segment Reporting Information [Line Items]          
SALES $ 479 $ 575 $ 884 $ 1,048  
OPERATING INCOME (LOSS) 51 21 (128) 4  
DEPRECIATION EXPENSE 45 63 79 120  
AMORTIZATION EXPENSE 15 20 32 40  
EBITDA [1] 111 104 (17) 164  
TOTAL ASSETS 5,233   5,233   $ 5,645
Intersegment Eliminations [Member]          
Segment Reporting Information [Line Items]          
SALES [2] (10) (13) (21) (24)  
Life Sciences [Member]          
Segment Reporting Information [Line Items]          
SALES 172 222 306 422  
OPERATING INCOME (LOSS) 28 50 42 82  
DEPRECIATION EXPENSE [3] 22 11 31 20  
AMORTIZATION EXPENSE 4 5 8 12  
EBITDA [1] 54 66 81 114  
TOTAL ASSETS 1,876   1,876   1,778
Life Sciences [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 172 222 306 422  
Personal Care [Member]          
Segment Reporting Information [Line Items]          
OPERATING INCOME (LOSS) 28 25 39 28  
DEPRECIATION EXPENSE 7 9 15 17  
AMORTIZATION EXPENSE 8 11 19 22  
EBITDA [1] 43 45 73 67  
TOTAL ASSETS 702   702   950
Personal Care [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 146 169 279 298  
Specialty Additives [Member]          
Segment Reporting Information [Line Items]          
SALES 134 157 249 279  
OPERATING INCOME (LOSS) 7 (18) 2 (50)  
DEPRECIATION EXPENSE [4] 13 40 27 77  
AMORTIZATION EXPENSE 3 4 5 6  
EBITDA [1] 23 26 34 33  
TOTAL ASSETS 1,355   1,355   1,516
Specialty Additives [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 134 157 249 279  
Intermediates [Member]          
Segment Reporting Information [Line Items]          
OPERATING INCOME (LOSS) (1) 9 2 16  
DEPRECIATION EXPENSE 3 3 6 6  
AMORTIZATION EXPENSE 0 0  
EBITDA [1] 2 12 8 22  
TOTAL ASSETS 119   119   127
Intermediates [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
SALES 37 40 71 73  
Unallocated and Other [Member]          
Segment Reporting Information [Line Items]          
OPERATING INCOME (LOSS) [5] (11) (45) (213) (72)  
EBITDA [1] (11) $ (45) (213) $ (72)  
TOTAL ASSETS $ 1,181   $ 1,181   $ 1,274
[1] Excludes income (loss) from discontinued operations and other net periodic benefit loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
[2] Intersegment sales from Intermediates are accounted for at prices that approximate fair value. All other intersegment sales are accounted for at cost.
[3] Depreciation includes accelerated depreciation of $13 million for Life Sciences for the three and six months ended March 31, 2025.
[4] Depreciation includes accelerated depreciation of $27 million and $49 million for Specialty Additives for the three and six months ended March 31, 2024, respectively.
[5] Includes a $8 million gain on sale for the three and six months ended March 31, 2025 and a $183 million impairment charge for the six months ended March 31, 2025, both related to the sale of the Avoca business within income (loss) on acquisitions and divestitures, net caption of the Statements of Condensed Consolidated Income (Loss).